Lancet journal13 Oct 2020 14:00
Ok it's a long read and mainly above me posted by Stevo on twitter
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30454-9/fulltext
My takes from it Qiagen were the pcr they don't appear to come out of it greatly
They are more concerned with the speed of poc?
In previous work, we showed that the routine use of point-of-care molecular testing for influenza and other respiratory viruses is associated with improvements in antiviral use and infection control measures, and that these effects are dependent on very short turnaround times that are not achievable in centralised laboratory testing.3, 4 Several rapid molecular platforms that can test for SARS-CoV-2 at the point of care have now been developed and are likely to reduce time to results, but there is little evidence for their clinical effect and real-world diagnostic accuracy.5, 6, 7, 8 The aim of this trial was to assess the clinical impact and real-world diagnostic accuracy of point-of-care testing using the QIAstat-Dx Respiratory SARS-CoV-2 Panel (Qiagen, Hilden, Germany) in adults presenting with suspected COVID-19 during the first wave of the pandemic in the UK
From table 2 poc 1.7 hrs lab 21.3 obviously at this time npt had not been considered.
Opinions?.